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OBJECTIVE — Of deceased pancreas donors, 3–4% may have autoantibodies (AAb) to pan-
creatic islet cell antigens; these autoantibodies are well-established markers of type 1 diabetes.
We investigated whether donor AAb positivity could affect the outcome of pancreas
transplantation.
RESEARCHDESIGNANDMETHODS — WeretrospectivelytestedAAbin135donors
whose pancreata and kidneys were transplanted in type 1 diabetes patients. We measured AAb
to glutamic acid decarboxylase (GAD-AAb), the tyrosine-phosphatase-like protein IA2 (IA2-
AAb), and insulin (insulin-AAb). We then evaluated pancreas transplant outcome data.
RESULTS — Four of 135 (2.96%) donors were AAb positive: three donors had GAD-AAb,
and one donor had insulin-AAb. Their respective recipients became insulin independent on
follow-up. Three of the four recipients had normal, insulin-producing grafts 3–5.8 years after
transplant. The recipient of the insulin-AAb–positive donor pancreas developed chronic rejec-
tion following discontinuation of immunosuppression 3.3 years after transplant.
CONCLUSIONS — Single AAb positivity did not affect the outcome of pancreas transplan-
tation in our study.
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T
ype 1 diabetes is an autoimmune dis-
easeresultingin-celllossandinsulin
dependence (1). Autoantibodies
(AAb)toseveralisletantigensarepredictive
and diagnostic for type 1 diabetes (2). The
presence of multiple AAb correlates with
higher disease risk in ﬁrst-degree relatives
(3). Simultaneous kidney-pancreas (SPK)
transplantation is therapeutic for type 1 di-
abetic patients with end-stage renal disease
(4).Studiessuggestthat3–4%oforgando-
nors have at least one AAb to islet cell anti-
gens (5,6). It is not known whether AAb
positivitycouldbeadonor-relatedfactoraf-
fectingtheoutcomeofpancreastransplants.
We performed retrospective AAb testing in
135 deceased donors whose pancreata and
kidneys had been transplanted in type 1 di-
abetic patients and then veriﬁed clinical
outcome.
RESEARCH DESIGN AND
METHODS—We have performed 350
SPK transplants over the past 18 years in
type1diabeticpatientswithend-stagere-
nal disease. Type 1 diabetes diagnosis is
routinely veriﬁed by lack of detectable C-
peptideafterasustacalchallenge.Allpan-
creas transplants are bladder drained (7).
We retrospectively tested AAb in 135 do-
nors (90 male and 45 female). The mean
age was 25.8 years (range 1.9–51). Pan-
creataandkidneysfromthetesteddonors
were transplanted into type 1 diabetic pa-
tients between 1998 and 2005. We mea-
suredAAbtoglutamicaciddecarboxylase
(GAD-AAb), the tyrosine-phosphatase-
like protein IA2 (IA2-AAb), and insulin
(insulin-AAb) using standard radioim-
munoassays. AAb levels are expressed as
index levels calculated from the counts
perminuteofthetestsampleandthepos-
itive and negative control samples. Re-
ceiver operating curves identiﬁed assay
cutoffs of 11.44, 3.72, and 6.85 for the
GAD, IA2, and insulin AAb assays, respec-
tively.OurlaboratoryparticipatedintheDi-
abetes Autoantibody Standardization
ProgramoftheImmunologyofDiabetesSo-
ciety and Centers for Disease Control in
2000, 2002, 2003, and 2005 (8). Donors
and recipients were HLA typed using stan-
dard serology. The institutional review
board of the University of Miami School of
Medicine approved the study.
RESULTS—Four of 135 (2.96%) do-
nors were AAb positive: three donors had
GAD-AAb, and one donor had insulin-
AAb. Donors with GAD-AAb had low
AAb levels. Donor 4 had markedly ele-
vated insulin-AAb levels. No donor had
IA2-AAb or multiple AAb. Tables 1 and 2
show the characteristics of the AAb-
positive donors and corresponding recip-
ients. Two donors with GAD-AAb were
homozygous for the HLA-DR4 or -DR3
susceptibility alleles; the remaining GAD-
AAb–positivedonorcarriedapresumably
protective HLA-DR2. The donor with in-
sulin-AAb had neutral HLA types.
We then evaluated outcome data
from the respective recipients. Our SPK
recipients had a mean  SD follow-up of
5  2.1 years. All patients transplanted
with a pancreas from a single AAb-
positive donor became insulin indepen-
dent; three-fourths of the patients
transplanted with a pancreas from an
AAb-positive donor had normal, insulin-
producing grafts 3–5.8 years after trans-
plant (Table 2). The recipient of the
pancreas from GAD-AAb–positive donor
1 had a pancreas transplant biopsy 3.2
years after transplantation showing no
-cell loss, insulitis, or other abnormali-
ties. This recipient had elevated GAD-
AAb levels preceding the transplant that
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follow-up. The recipient of the pancreas
from insulin-AAb–positive donor 4 de-
veloped chronic rejection following dis-
continuation of immunosuppression 3.3
years after transplant. At that time, GAD-
AAbweretransientlypositive.Thepatient
returned to insulin dependency despite
maintaining residual C-peptide secretion
for up to 2.2 years after developing
chronic rejection. The patient’s last C-
peptide level was 2.3 ng/ml. Loss of graft
function did not differ among recipients
ofAAb-positiveandAAb-negativedonors
(1 of 4 vs. 12 of 131; P  0.33).
CONCLUSIONS —There is interest
in screening pancreas donors for autoan-
tibodies to identify pre-diabetic donor
pancreata that may not be suitable for
transplantation and could be made avail-
able for research (5). The Juvenile Diabe-
tes Research Foundation is supporting
large-scale screening to identify AAb-
positive pancreas donors for research
(www.jdrfnpod.org). A recent analysis of
pancreas donors aged 25–60 years from
thegeneralpopulationshowedthatsingle
AAb positivity is not commonly associ-
ated with insulitis and -cell loss, via an-
alyzing 0.5 cm
3 bioptic fragments of
pancreata that were used for islet cell iso-
lation (6). Insulitis was found in only two
donors who were positive for 3 AAb and
not in 59 donors positive for 1–2 AAb.
We identiﬁed four donors with a single
AAb, consistent with the reported fre-
quency in organ donors (5). Our data in-
clude subjects younger than those in
previous studies (5,6): of our donors, 55%
were aged 25 years, an age-group with
higher type 1 diabetes incidence. Indeed,
this group yielded three of the four AAb-
positive donors. Our analysis is unique in
providingtransplantoutcomedatafrompa-
tientswhoreceivedapancreasfromasingle
AAb-positivedonor.Allpatientsbecamein-
sulin independent on follow-up. In a pa-
tient who continued to be euglycemic, a
biopsy performed 3 years after transplanta-
tion did not evidence islet damage. The re-
cipient of the insulin-AAb–positive donor
pancreas lost transplant function due to
chronicrejectionrelatedtononcompliance.
Overall, our outcome data are consistent
with biopsy data from previous studies
showing that single AAb positivity may not
always be associated with clinically signiﬁ-
cant autoimmunity and -cell damage in
organdonors(5,6).Theﬁndingsareconsis-
tent with the low diabetes risk associated
with single AAb positivity in the general
population (9,10). Relevant to clinical pan-
creas transplantation, our data suggest that
single autoantibody positivity is unlikely to
affectpancreastransplantoutcomeandmay
help to reﬁne strategies for ongoing pan-
creas donor AAb-screening initiatives, of
which we remain strong supporters. Lim-
ited access to human pancreata with ongo-
ingautoimmunityremainsamajorobstacle
totheadvancementofourunderstandingof
human type 1 diabetes.
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Table 1—Age distribution and HLA-DR types of pancreas donors
Age-group
(years) n
Non-
DR3/4 DR3/X DR4/X DR3/4
10 7 2 3 2 0
11–20 43 24 11 7 1
21–30 36 23 5 7 1
31–40 35 19 4 12 0
41–50 14 7 3 3 1
Total 135 75 26 31 3
Table 2—AAb status, age, HLA types, and clinical outcome data for AAb-positive donors and
respective recipients
Donors Recipients
Positive
AAb
Index
levels
Age
(years) HLA
Clinical
outcome
Follow-up
(years)
Age
(years) HLA
GAD-
AAb IA2-AAb
1 GAD 18 41 DR4/4 NGT 4.4 48 DR3/4 Positive Positive
2 GAD 19.9 22 DR1/2 NGT 3 38 DR3/4 Negative Negative
3 GAD 19.3 5 DR3/3 NGT 5.8 39 DR3/7 Positive Positive
4 Insulin 162 19 DR6/7 PCR 6.8 44 DR1 Positive* Negative
*SPK recipient 4 expressed GAD-AAb transiently following chronic rejection. NGT, normal glucose toler-
ance; PCR, pancreatic chronic rejection.
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